Recap: Fate Therapeutics Q3 Earnings
Portfolio Pulse from Benzinga Insights
Fate Therapeutics (NASDAQ:FATE) reported its Q3 earnings, beating estimated earnings by 19.3% with an EPS of $-0.46 versus an estimate of $-0.57. However, revenue was down $13.04 million from the same period last year. Last quarter, the company beat on EPS by $0.05, which was followed by a 3.68% drop in the share price the next day.
November 08, 2023 | 9:20 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Fate Therapeutics beat Q3 earnings estimates but reported a decrease in revenue. Past performance shows a drop in share price following a beat on EPS.
Fate Therapeutics beat earnings estimates, which is generally a positive signal. However, the company reported a decrease in revenue, which is a negative signal. Additionally, past performance shows that the company's share price dropped following a beat on EPS last quarter, which could indicate a similar trend this quarter.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100